Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04612374
Recruitment Status : Recruiting
First Posted : November 3, 2020
Last Update Posted : January 5, 2021
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:

Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conducted in two phases. In the Phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: The Unified Protocol. This treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. After treatment, patients will provide feedback about their experience. The investigators will use this feedback to revise the treatment as indicated. In Phase 2, participants will receive the revised treatment and provide feedback on their experience. Throughout treatment in either phase, participants will provide daily and weekly information about their symptoms.

The aims of this study are (1) to explore the acceptability and feasibility of the Unified Protocol for individuals who experience Misophonia and (2) to examine whether this treatment helps reduce symptoms associated with Misophonia.


Condition or disease Intervention/treatment Phase
Misophonia Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Behavioral: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia
Actual Study Start Date : December 21, 2020
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1: Unified Protocol, 2 week baseline
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Please see arm/group descriptions

Experimental: Phase 1: Experimental: Unified Protocol, 4 week baseline
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Please see arm/group descriptions

Experimental: Phase 2: Revised Unified Protocol, 2 week baseline
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
Behavioral: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Please see arm/group descriptions

Experimental: Phase 2: Revised Unified Protocol, 4 week baseline
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
Behavioral: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Please see arm/group descriptions




Primary Outcome Measures :
  1. Number of patients that are satisfied with treatment as measured by the credibility and expectancy questionnaire (CEQ [ Time Frame: up to 20 weeks ]
    The CEQ is a 6-item measure that asks patients about their perceptions of treatment.

  2. Number of patients who indicate treatment was acceptable to them (i.e., the treatment approach made sense and was perceived as reasonable) [ Time Frame: up to 20 weeks ]
    The Satisfaction with Therapy and Therapist Scale is a 13-item measure that asks patients about their satisfaction with treatment and with their therapist.

  3. Number of sessions attended [ Time Frame: up to 20 weeks ]
    The number of sessions attended will provide an estimate of the feasibility of attending and completing this treatment

  4. Number of patients who use mindfulness skills assessed by the Southampton Mindfulness Questionnaire (SMQ) [ Time Frame: up to 24 weeks ]
    The SMQ is a 16-item measure that asks patients about their use of mindfulness skills .

  5. Number of patients who use cognitive flexibility skills assessed by the UP Cognitive Skills Questionnaire (CSQ) [ Time Frame: up to 24 weeks ]
    The CSQ is a 10-item measure that assesses use of cognitive skills taught in treatment

  6. Number of Patients who use behavior change skills assessed by the UP Behavioral Avoidance Questionnaire (BAQ) [ Time Frame: up to 24 weeks ]
    The BAQ is a five item measure that assesses use of behavior change skills taught in treatment.

  7. Number of patients who report a decrease in anxiety sensitivity on the Anxiety Sensitivity Index (ASI) [ Time Frame: up to 24 weeks ]
    The ASI is an 18 measure that assesses how often a participant experiences anxiety symptoms

  8. Number of Patients who use behavior change skills assessed by the Brief Experiential Avoidance Questionnaire (BEAQ) [ Time Frame: up to 24 weeks ]
    The BEAQ is a 13 item measure that assesses how often a participant avoids emotion-provoking situations

  9. Change in misophonia symptoms as assessed by the Misophonia Questionnaire [ Time Frame: assessed weekly, up to 24 weeks ]
    The Misophonia Questionnaire is a 17-item questionnaire that assesses the presence of misophonia symptoms, emotions and behaviors associated with misophonic reactions, and symptom severity. The first two subscales are rated on a scale of 0 (not at all true) to 4 (always true). These two parts are summed to produce a total score ranging from 0 - 68. The severity subscale is a single item that asks an individual to provide a rating of their sound sensitivity on a scale from 0 (no sound sensitivities) to 15 (very severe sound sensitivities).

  10. Change in anxiety as measured by the Overall Anxiety Severity and Impairment Scale [ Time Frame: assessed weekly, up to 24 weeks ]
    The Overall Anxiety Severity and Impairment Scale is a five item measure that assesses interference and distress related to the experience of anxiety. Items are scored from 0 to 4 and summed to produce a total score (ranging from 0 - 20), with higher scores indicating greater functional impairment.

  11. Change in depression as measured by the Overall Depression Severity and Impairment Scale [ Time Frame: assessed weekly, up to 24 weeks ]
    The Overall Depression Severity and Impairment Scale is a five item measure that assesses interference and distress in an individual's day-to-day life related to the experience of depression. Items are scored from 0 to 4 and summed to produce a total score (ranging from 0 - 20), with higher scores indicating greater functional impairment.

  12. Change in anger as measured by the PANAS Hostility Scale [ Time Frame: assessed weekly, up to 24 weeks ]
    The PANAS Hostility Scale is a 6 item scale that assesses how often a participant experienced anger in the past week.


Secondary Outcome Measures :
  1. Number of patients who report a change in attentional control as measured by the Digit Span Test [ Time Frame: up to 20 weeks ]
    This test assesses a participant's ability to selectively use their attention during a task

  2. Number of patients who report a change in attentional control as measured by the Trail Making Test [ Time Frame: up to 20 weeks ]
    This test assesses a participant's ability to selectively use their attention during a task

  3. Number of patients who report a change in cognitive flexibility as measured by the Stroop test [ Time Frame: up to 20 weeks ]
    This test assesses a participant's ability to alternate their responses based on instructions.

  4. Number of patients who report a change in cognitive flexibility as measured by the Trail Making Test [ Time Frame: up to 20 weeks ]
    This test assesses a participant's ability to alternate their responses based on instructions.

  5. Number of seconds participant engaged in a physiological challenge exercise [ Time Frame: up to 20 weeks ]
    Participants will be asked to breathe through a small straw, with the option to stop at any time

  6. Number of seconds participant engaged in a writing task [ Time Frame: up to 20 weeks ]
    Participants will be asked to write about emotion-provoking situations, with the option to stop at any time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Between age 18-65
  • Able to read English
  • Meet criteria for interfering symptoms of misophonia
  • Live in North Carolina

Exclusion Criteria:

  • Under age 18 or over age 65
  • Current mania
  • Current psychotic disorder
  • Current anorexia
  • Presents with a condition that requires immediate prioritization in treatment (e.g., suicide planning or intent)

Phase 1 participants cannot also participate in Phase 2.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04612374


Contacts
Layout table for location contacts
Contact: Clair Robbins, Ph.D. 919-684-9486 clair.robbins@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27701
Contact: Clair Robbins       clair.robbins@duke.edu   
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: M. Zachary Rosenthal, PhD Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04612374    
Other Study ID Numbers: Pro00106807
First Posted: November 3, 2020    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Duke University:
Misophonia
Treatment